comprehensive -WSS

comprehensive

author：leisure time 2025-10-01 01:50:32 - browse：735

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： The biotech scorecard for Q3: 15 stock

hotspot

WSS

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

What affirmative action's end means to a medical student

CDC's new outbreak response network to include Northeastern

Thermo Fisher plant for manufacturing gene therapies to expand

Senate HELP committee spars over health care workforce policies

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

hotspot

comprehensive

knowledge

Novavax promises a turnaround & Lilly roils the obesity market

Drug for rare kidney disease narrowly misses mark in clinical trial

Moonlake's readout produced a cash windfall. Risks remain

Ukraine and a new approach to mental health in war

State Dept. review finds Biden bears some blame for Afghanistan failures

What affirmative action's end means to a medical student

Medicare details structure of new drug price negotiation program

Microbiome research is starting to find links to chronic diseases

United colonoscopy coverage change 'may cost lives,' doctors say

Senators: Long

knowledge

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

It's been 20 years since Dolly the sheep. Where's my clone?

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

EpiPen alternative approval delay highlights citizen petition issue

Second xenotransplant done with gene

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

entertainment

knowledge

hotspot

focus